1. Angiogenesis-related non-coding RNAs and gastrointestinal cancer
- Author
-
Kasra Asgarpour, Zahra Sadat Razavi, Maryam Mahjoubin-Tehran, Mohammad Karim Shahrzad, Haroon Khan, Michael R. Hamblin, Susan Rasouli, and Hamed Mirzaei
- Subjects
0301 basic medicine ,Cancer Research ,Angiogenesis ,Review ,Metastasis ,angiogenesis ,long non-coding RNAs ,03 medical and health sciences ,0302 clinical medicine ,microRNA ,medicine ,Pharmacology (medical) ,Gastrointestinal cancer ,gastrointestinal cancers ,Cancer death ,RC254-282 ,business.industry ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,medicine.disease ,microRNAs ,Cancer treatment ,030104 developmental biology ,Oncology ,030220 oncology & carcinogenesis ,Cancer cell ,Cancer research ,non-coding RNAs ,Molecular Medicine ,business ,Gi cancer ,circular RNAs - Abstract
Gastrointestinal (GI) cancers are among the main reasons for cancer death globally. The deadliest types of GI cancer include colon, stomach, and liver cancers. Multiple lines of evidence have shown that angiogenesis has a key role in the growth and metastasis of all GI tumors. Abnormal angiogenesis also has a critical role in many non-malignant diseases. Therefore, angiogenesis is considered to be an important target for improved cancer treatment. Despite much research, the mechanisms governing angiogenesis are not completely understood. Recently, it has been shown that angiogenesis-related non-coding RNAs (ncRNAs) could affect the development of angiogenesis in cancer cells and tumors. The broad family of ncRNAs, which include long non-coding RNAs, microRNAs, and circular RNAs, are related to the development, promotion, and metastasis of GI cancers, especially in angiogenesis. This review discusses the role of ncRNAs in mediating angiogenesis in various types of GI cancers and looks forward to the introduction of mimetics and antagonists as possible therapeutic agents., Graphical abstract, Deregulation of many types of ncRNAs can affect angiogenesis and metastasis in GI cancers. The rapid development of different types of mimetics or antagonists of specific ncRNAs, as well as more effective delivery technologies has raised the possibility to employ ncRNAs as targets to treat metastatic GI cancers.
- Published
- 2021